Abstract
This trial was undertaken to test the hypothesis that two-drug initial therapy for acute graft-versus-host disease (GVHD) would produce better control of GVHD and less exposure to corticosteroids than the standard treatment of corticosteroids alone. All participants had undergone allogeneic hematopoietic stem cell transplantation (HSCT) and developed acute GVHD. Subjects were randomized to treatment with corticosteroids plus placebo or corticosteroids plus daclizumab. The trial was continued past its first interim analysis (~30%; evaluable subjects) but was stopped after the second interim analysis (~50%; evaluable subjects) when the two-drug arm was associated with worse overall survival.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. 1990. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75:1024–1030.
Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. 1998. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968.
Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. 1990. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76:1464–1472.
MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. 2002. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8:387–394.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1995. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825–828.
Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, Edwards N, Mancini DM. 2000. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody [comment]. N Engl J Med 342:613–619.
Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F. Phase III Daclizumab Study Group. 2001. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72:839–845.
Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. 2003. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326:789.
Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. 2000. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83–89.
O’Brien PC, Fleming TR. 1979. A multiple testing procedure for clinical trials. Biometrics 35:549–556.
Jennison C, Turnbull BW. 1989. The repeated confidence interval approach. J Royal Stat Soc 51:305–334.
Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, et al. 2004. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial. Blood 104:1559–1564.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Zahrieh, D., Lee, S.J., Harrington, D. (2006). Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_25
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_25
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)